High on Treatment Platelet Reactivity

Serruys, 1991, Angiographic follow-up after placement of a self-expanding coronary-artery stent, N Engl J Med, 324, 13, 10.1056/NEJM199101033240103 Haude, 1993, Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents, Am Heart J, 126, 15, 10.1016/S0002-8703(07)80005-6 Gurbel, 2007, Platelet function monitoring in patients with coronary artery disease, J Am Coll Cardiol, 50, 1822, 10.1016/j.jacc.2007.07.051 Savi, 2005, Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis, Semin Thromb Hemost, 31, 174, 10.1055/s-2005-869523 Michelson, 2006, Current options in platelet function testing, Am J Cardiol, 98, 4N, 10.1016/j.amjcard.2006.09.008 Michelson, 2009, Methods for the measurement of platelet function, Am J Cardiol, 103, 20A, 10.1016/j.amjcard.2008.11.019 Serebruany, 2005, Variability in platelet responsiveness to clopidogrel among 544 individuals, J Am Coll Cardiol, 45, 246, 10.1016/j.jacc.2004.09.067 Price, 2009, Bedside evaluation of thienopyridine antiplatelet therapy, Circulation, 119, 2625, 10.1161/CIRCULATIONAHA.107.696732 Blindt, 2007, The signification of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis, Thromb Haemost, 98, 1329, 10.1160/TH07-05-0324 Geisler, 2008, The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score, J Thromb Haemost, 6, 54, 10.1111/j.1538-7836.2007.02812.x Price, 2008, Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation, Eur Heart J, 29, 992, 10.1093/eurheartj/ehn046 Bonello, 2008, Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study, J Am Coll Cardiol, 51, 1404, 10.1016/j.jacc.2007.12.044 Sibbing, 2009, Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis, J Am Coll Cardiol, 53, 849, 10.1016/j.jacc.2008.11.030 Cuisset, 2009, Predictive values of post-treatment adenosinediphosphate induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients, Am J Cardiol, 104, 1078, 10.1016/j.amjcard.2009.06.007 Bonello, 2007, Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events, J Thromb Haemost, 5, 1630, 10.1111/j.1538-7836.2007.02609.x Patti, 2008, J Am Coll Cardiol, 52, 1128, 10.1016/j.jacc.2008.06.038 Angiolillo, 2007, Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study, Circulation, 115, 708, 10.1161/CIRCULATIONAHA.106.667741 Michelson, 2009, TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial, Eur Heart J, 30, 1753, 10.1093/eurheartj/ehp159 Wang, 2006, Aspirin and clopidogrel resistance: an emerging clinical entity, Eur Heart J, 27, 647, 10.1093/eurheartj/ehi684 Gawaz, 1996, Platelet function in acute myocardial infarction treated with direct angioplasty, Circulation, 93, 229, 10.1161/01.CIR.93.2.229 Serebruany, 2003, Effect of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial, Am Heart J, 146, 713, 10.1016/S0002-8703(03)00260-6 Soffer, 2003, Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?, Cathet Cardiovasc Intervent, 59, 21, 10.1002/ccd.10494 Poulsen, 2005, Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Reevaluating the evidence, Basic Clin Pharmacol Toxicol, 96, 103, 10.1111/j.1742-7843.2005.pto960203.x Gurbel, 2003, Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 Angiolillo, 2004, Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loadingdose be weight adjusted?, J Invasive Cardiol, 16, 169 Cuisset, 2009, Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response, Thromb Res, 123, 597, 10.1016/j.thromres.2008.04.003 Sibbing, 2007, Impact of body mass index on platelet aggregation after administration of a high loading dose of 600mg of Clopidogrel before percutaneous coronary intervention, Am J Cardiol, 100, 203, 10.1016/j.amjcard.2007.02.081 Bonello-Palot, 2009, Relation of body mass index to high on-treatment platelet reactivity and of failed Clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention, Am J Cardiol, 104, 1511, 10.1016/j.amjcard.2009.07.015 Scherrer, 1991, Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium, Circulation, 83, 552, 10.1161/01.CIR.83.2.552 Kotlyar, 1999, Effects of obesity on the cytochromes P450 enzyme system, Int J Pharmacol Ther, 37, 8 Angiolillo, 2005, Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment, Diabetes, 54, 2430, 10.2337/diabetes.54.8.2430 Angiolillo, 2006, Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment, J Am Coll Cardiol, 48, 298, 10.1016/j.jacc.2006.03.038 Geisler, 2007, Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation, Diabetes Care, 30, 372, 10.2337/dc06-1625 Serebruany, 2008, Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease, Thromb Haemost, 100, 76, 10.1160/TH08-03-0136 Ferroni, 2004, Platelet activation in type 2 diabetes mellitus, J Thromb Haemost, 2, 1282, 10.1111/j.1538-7836.2004.00836.x Ferreira, 2004, IRS-1 mediates inhibition of Ca+2 metabolization of insulin via the inhibitory G protein Gi, J Biol Chem, 279, 3254, 10.1074/jbc.M305474200 Ferreira, 2006, Platelet inhibition by insulin is absent in type 2 diabetes mellitus, Arterioscler Thromb Vasc Biol, 26, 417, 10.1161/01.ATV.0000199519.37089.a0 Ishizaki, 1999, Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole, Aliment Pharmacol Ther, 13, 27, 10.1046/j.1365-2036.1999.00022.x Horn, 2004, Review article: relationship between the metabolism and efficacy of proton pump inhibitors—focus on rabeprazole, Aliment Pharmacol Ther, 20, 11, 10.1111/j.1365-2036.2004.02161.x Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064 Gilard, 2006, Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin, J Thromb Haemost, 4, 2508, 10.1111/j.1538-7836.2006.02162.x Simon, 2009, Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, 363, 10.1056/NEJMoa0808227 Collet, 2009, Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study, Lancet, 373, 309, 10.1016/S0140-6736(08)61845-0 Siller-Matula, 2009, Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel, Am Heart J, 157, 148, 10.1016/j.ahj.2008.09.017 Kwok, 2010, Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving Clopidogrel, Aliment Pharmacol Ther, 31, 810 Bhatt, 2010, Clopidogrel with or without omeprazole in coronary artery disease, COGENT Investigators, N Engl J Med, 363, 1909, 10.1056/NEJMoa1007964 Siller-Matula, 2008, Calcium-channel blockers reduce the antiplatelet effect of clopidogrel, J Am Coll Cardiol, 52, 1557, 10.1016/j.jacc.2008.07.055 Olesen, 2011, Calcium-channel blockers do not alter the clinical efficacy of Clopidogrel after myocardial infarction: a Nationwide Cohort Study, J Am Coll Cardiol, 57, 409, 10.1016/j.jacc.2010.08.640 French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators, 2009, Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, 363, 10.1056/NEJMoa0808227 Hochholzer, 2005, Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention, Circulation, 111, 2560, 10.1161/01.CIR.0000160869.75810.98 Collet, 2008, Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the reload with Clopidogrel before coronary angioplasty in subjects treated long term with dual antiplatelet therapy (RELOAD) study, Circulation, 118, 1225, 10.1161/CIRCULATIONAHA.108.776757 Angiolillo, 2004, High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability, Eur Heart J, 25, 1903, 10.1016/j.ehj.2004.07.036 Gurbel, 2006, Drug insight: Clopidogrel nonresponsiveness, Nat Clin Pract Cardiovasc Med, 3, 387, 10.1038/ncpcardio0602 Nebert, 2002, Clinical importance of the cytochromes P450, Lancet, 360, 1155, 10.1016/S0140-6736(02)11203-7 Nguyen, 2005, Resistance to clopidogrel: a review of the evidence, J Am Coll Cardiol, 45, 1157, 10.1016/j.jacc.2005.01.034 Angiolillo, 2005, Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease, Thromb Haemost, 116, 491 Von Beckerath, 2005, Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088 Bonello, 2010, Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel doseadjustment according to platelet reactivity monitoring in coronary artery disease patients, Thromb Res, 125, e167, 10.1016/j.thromres.2009.10.014 Von Beckerath, 2005, P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphateinduced platelet aggregation after initiation of clopidogrel therapy with a high loading dose, Blood Coagul Fibrinolysis, 16, 199, 10.1097/01.mbc.0000164429.21040.0a Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052 Brandt, 2007, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel, J Thromb Haemost, 5, 2429, 10.1111/j.1538-7836.2007.02775.x Umemura, 2008, The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects, J Thromb Haemost, 6, 1439, 10.1111/j.1538-7836.2008.03050.x Giusti, 2007, Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 +12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients, Pharmacogenet Genomics, 17, 1057, 10.1097/FPC.0b013e3282f1b2be Frere, 2008, Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome, Am J Cardiol, 101, 1088, 10.1016/j.amjcard.2007.11.065 Trenk, 2008, Cytochrome P450 2C19 681GNA polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents, J Am Coll Cardiol, 51, 1925, 10.1016/j.jacc.2007.12.056 Trenk, 2008, Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement, Thromb Haemost, 99, 174, 10.1160/TH07-08-0503 Mega, 2010, Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis, Lancet, 10.1016/S0140-6736(10)61273-1 Wallentin, 2010, Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial, Lancet, 376, 1320, 10.1016/S0140-6736(10)61274-3 Barragan, 2003, Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation, Catheter Cardiovasc Interv, 59, 295, 10.1002/ccd.10497 Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03 Bliden, 2007, Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?, J Am Coll Cardiol, 49, 657, 10.1016/j.jacc.2006.10.050 Hochholzer, 2006, Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement, J Am Coll Cardiol, 48, 1742, 10.1016/j.jacc.2006.06.065 Buonamici, 2007, Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis, J Am Coll Cardiol, 49, 2312, 10.1016/j.jacc.2007.01.094 Lev, 2007, Platelet reactivity in patients with subacute stent thrombosis compared with nonstent-related acute myocardial infarction, Am Heart J, 153, e1, 10.1016/j.ahj.2006.10.020 Geisler, 2006, Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation, Eur Heart J, 27, 2420, 10.1093/eurheartj/ehl275 Collet, 2011, Am Heart J, 161, 5, 10.1016/j.ahj.2010.09.029 Cuisset, 2006, Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting, J Am Coll Cardiol, 48, 1339, 10.1016/j.jacc.2006.06.049 von Beckerath, 2007, A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75mg of clopidogrel for 30 days, Eur Heart J, 28, 1814, 10.1093/eurheartj/ehl489 Patti, 2005, Circulation, 111, 2099, 10.1161/01.CIR.0000161383.06692.D4 Angiolillo, 2007, Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study, Circulation, 115, 708, 10.1161/CIRCULATIONAHA.106.667741 Lemesle, 2009, Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome, Am Heart J, 375, 10.1016/j.ahj.2008.09.013 Bonello, 2010, Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2 loss of function polymorphism, Int J Cardiol, 145, 165, 10.1016/j.ijcard.2009.07.033 Price, 2011, Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.; GRAVITAS Investigators, JAMA, 305, 1097, 10.1001/jama.2011.290 Tanaka, 1988, Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle, Pharmacology, 36, 313, 10.1159/000138400 Park, 1999, Comparison of cilostazol versus ticlopidine therapy after stent implantation, Am J Cardiol, 84, 511, 10.1016/S0002-9149(99)00368-9 Lee, 2005, Comparison of cilostazol and clopidogrel after successful coronary stenting, Am J Cardiol, 95, 859, 10.1016/j.amjcard.2004.12.012 Lee, 2005, Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis, J Am Coll Cardiol, 46, 1833, 10.1016/j.jacc.2005.07.048 Cuisset, 2008, Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study, JACC Cardiovasc Interv, 1, 649, 10.1016/j.jcin.2008.08.018 TRITON-TIMI 38 Investigators, 2009, Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial, Eur Heart J, 30, 1753, 10.1093/eurheartj/ehp159 Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 2001, 10.1056/NEJMoa0706482 Wallentin, 2000, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, 1045, 10.1056/NEJMoa0904327